Latest post

A strategic focus for Oxurion: researching and developing non-VEGF pathways

Jean Feyen, PhD., Chief Scientific Officer, and Andy De Deene, M.D., Global Head of Development, explain why Oxurion decided to focus on non-VEGF pathways.

eye community

“Cutting-edge research can change people’s lives”

“Partnerships with the industry and biotech companies like Oxurion are crucial to us,” says Jeff Todd, President & CEO of Prevent Blindness US.